Chardan Capital Brokers Decrease Earnings Estimates for NTLA

Intellia Therapeutics, Inc. (NASDAQ:NTLA - Free Report) - Investment analysts at Chardan Capital reduced their FY2025 earnings estimates for shares of Intellia Therapeutics in a note issued to investors on Monday, November 18th. Chardan Capital analyst Y. Livshits now expects that the company will post earnings per share of ($4.14) for the year, down from their previous forecast of ($4.02). Chardan Capital currently has a "Buy" rating and a $91.00 target price on the stock. The consensus estimate for Intellia Therapeutics' current full-year earnings is ($5.13) per share.

NTLA has been the subject of several other reports. Evercore ISI raised shares of Intellia Therapeutics to a "strong-buy" rating in a research note on Friday, August 9th. Wells Fargo & Company dropped their price objective on shares of Intellia Therapeutics from $80.00 to $70.00 and set an "overweight" rating for the company in a research note on Monday. William Blair reissued a "neutral" rating and issued a $14.00 price objective on shares of Intellia Therapeutics in a research note on Monday. Royal Bank of Canada reissued an "outperform" rating and issued a $54.00 price objective on shares of Intellia Therapeutics in a research note on Thursday, September 19th. Finally, The Goldman Sachs Group dropped their price objective on shares of Intellia Therapeutics from $31.00 to $20.00 and set a "neutral" rating for the company in a research note on Friday, October 25th. One equities research analyst has rated the stock with a sell rating, six have assigned a hold rating, eleven have issued a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $54.94.

Intellia Therapeutics Trading Up 5.2 %

NTLA traded up $0.68 during trading on Thursday, hitting $13.80. 3,959,241 shares of the company traded hands, compared to its average volume of 1,729,794. The company has a market cap of $1.41 billion, a PE ratio of -2.58 and a beta of 1.81. The stock's 50-day simple moving average is $18.26 and its two-hundred day simple moving average is $21.85. Intellia Therapeutics has a 1 year low of $12.82 and a 1 year high of $34.87.

Intellia Therapeutics (NASDAQ:NTLA - Get Free Report) last announced its quarterly earnings data on Thursday, November 7th. The company reported ($1.34) EPS for the quarter, beating the consensus estimate of ($1.37) by $0.03. The firm had revenue of $9.10 million for the quarter, compared to the consensus estimate of $8.28 million. The firm's revenue for the quarter was down 24.1% on a year-over-year basis. During the same quarter in the previous year, the business earned ($1.38) earnings per share.

Insider Activity at Intellia Therapeutics

In other news, CAO Michael P. Dube sold 2,012 shares of the business's stock in a transaction dated Wednesday, October 2nd. The shares were sold at an average price of $19.01, for a total value of $38,248.12. Following the completion of the sale, the chief accounting officer now owns 47,012 shares in the company, valued at approximately $893,698.12. The trade was a 4.10 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 3.20% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Intellia Therapeutics

Large investors have recently modified their holdings of the business. Blue Trust Inc. raised its holdings in shares of Intellia Therapeutics by 1,664.3% in the 2nd quarter. Blue Trust Inc. now owns 1,482 shares of the company's stock valued at $33,000 after purchasing an additional 1,398 shares in the last quarter. EverSource Wealth Advisors LLC raised its holdings in shares of Intellia Therapeutics by 763.5% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 1,753 shares of the company's stock valued at $39,000 after purchasing an additional 1,550 shares in the last quarter. Eastern Bank bought a new stake in shares of Intellia Therapeutics in the 3rd quarter valued at about $41,000. First Horizon Advisors Inc. raised its holdings in shares of Intellia Therapeutics by 22.1% in the 2nd quarter. First Horizon Advisors Inc. now owns 2,604 shares of the company's stock valued at $58,000 after purchasing an additional 472 shares in the last quarter. Finally, Values First Advisors Inc. bought a new stake in shares of Intellia Therapeutics in the 3rd quarter valued at about $54,000. Institutional investors own 88.77% of the company's stock.

Intellia Therapeutics Company Profile

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.